| scholarly article | Q13442814 |
| P50 | author | J Spencer Hauck | Q85603165 |
| Elise P Gomez-Sanchez | Q87889131 | ||
| Jill A Rafael-Fortney | Q87889133 | ||
| P2093 | author name string | Celso E Gomez-Sanchez | |
| Jessica A Chadwick | |||
| P2860 | cites work | Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor | Q22254872 |
| Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy | Q24310537 | ||
| The ubiquitous mineralocorticoid receptor: clinical implications | Q26861721 | ||
| Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources | Q27860739 | ||
| The steroid and thyroid hormone receptor superfamily | Q27861095 | ||
| Natriuretic peptide receptor-C signaling and regulation | Q28252424 | ||
| Glucocorticoid-treated mice are an inappropriate positive control for long-term preclinical studies in the mdx mouse | Q28482090 | ||
| X chromosome-linked muscular dystrophy (mdx) in the mouse | Q28589078 | ||
| Multiple aspects of mineralocorticoid selectivity | Q32031971 | ||
| Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury | Q32073071 | ||
| ADAMTS1 interacts with, cleaves, and modifies the extracellular location of the matrix inhibitor tissue factor pathway inhibitor-2. | Q33241217 | ||
| A review of statistical methods for preprocessing oligonucleotide microarrays. | Q33682929 | ||
| The biology of the glucocorticoid receptor: new signaling mechanisms in health and disease | Q33854747 | ||
| The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation | Q33911291 | ||
| Transcriptional hyperactivity of human progesterone receptors is coupled to their ligand-dependent down-regulation by mitogen-activated protein kinase-dependent phosphorylation of serine 294. | Q33969423 | ||
| Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands. | Q34347790 | ||
| Mineralocorticoid receptor antagonists-pharmacodynamics and pharmacokinetic differences | Q34516792 | ||
| New ideas about aldosterone signaling in epithelia | Q34552939 | ||
| Circadian rhythm gene period 3 is an inhibitor of the adipocyte cell fate. | Q34684926 | ||
| Cardiac ankyrin repeat protein is a marker of skeletal muscle pathological remodelling | Q34921653 | ||
| VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects | Q34981147 | ||
| ToppGene Suite for gene list enrichment analysis and candidate gene prioritization | Q34982758 | ||
| Tissue engineering of articular cartilage with biomimetic zones | Q35064145 | ||
| Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy. | Q35097376 | ||
| Aldosterone: its receptor, target genes, and actions | Q35173847 | ||
| Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial | Q35181260 | ||
| Brain mineralocorticoid receptors: orchestrators of hypertension and end-organ disease | Q35808501 | ||
| Ligand-dependent degradation of SRC-1 is pivotal for progesterone receptor transcriptional activity | Q35874237 | ||
| The multifaceted mineralocorticoid receptor | Q35906989 | ||
| Mineralocorticoid receptors are present in skeletal muscle and represent a potential therapeutic target. | Q36171304 | ||
| The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology | Q36238325 | ||
| Disinhibitory pathways for control of sodium transport: regulation of ENaC by SGK1 and GILZ. | Q36487028 | ||
| The glucocorticoid receptor: cause of or cure for obesity? | Q36817359 | ||
| The Angiotensin Converting Enzyme Inhibitor Lisinopril Improves Muscle Histopathology but not Contractile Function in a Mouse Model of Duchenne Muscular Dystrophy | Q36817631 | ||
| Haploinsufficiency of utrophin gene worsens skeletal muscle inflammation and fibrosis in mdx mice | Q37227124 | ||
| Immunohistochemical demonstration of the mineralocorticoid receptor, 11beta-hydroxysteroid dehydrogenase-1 and -2, and hexose-6-phosphate dehydrogenase in rat ovary | Q37234861 | ||
| Glucocorticoid- and protein kinase A-dependent transcriptome regulation in airway smooth muscle | Q37241622 | ||
| The mineralocorticoid receptor and its coregulators. | Q37555824 | ||
| Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management | Q37640907 | ||
| Renal mineralocorticoid receptors and hippocampal corticosterone-binding species have identical intrinsic steroid specificity | Q37690385 | ||
| The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights | Q37732574 | ||
| Tissue-specific modulation of mineralocorticoid receptor function by 11β-hydroxysteroid dehydrogenases: an overview | Q37912407 | ||
| Muscle ankyrin repeat proteins: their role in striated muscle function in health and disease | Q37970139 | ||
| Metabolic functions of glucocorticoid receptor in skeletal muscle | Q38092488 | ||
| Mineralocorticoids in the heart and vasculature: new insights for old hormones | Q38253950 | ||
| Prednisolone-induced changes in dystrophic skeletal muscle | Q38330039 | ||
| Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1. | Q38850114 | ||
| The intracellular localization of the mineralocorticoid receptor is regulated by 11beta-hydroxysteroid dehydrogenase type 2. | Q40806489 | ||
| Steroid hormone stimulation of Na+ transport in A6 cells is mediated via glucocorticoid receptors | Q41561492 | ||
| The role of 11 beta-hydroxysteroid dehydrogenase in the pathogenesis of hypertension | Q42540734 | ||
| Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in Duchenne muscular dystrophy mice. | Q42855263 | ||
| Attenuation of adverse cardiac effects in prednisolone-treated delta-sarcoglycan-deficient mice by mineralocorticoid-receptor-antagonism | Q43242415 | ||
| Spironolactone blocks glucocorticoid-mediated hearing preservation in autoimmune mice | Q43914103 | ||
| Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties | Q45055404 | ||
| Myeloid cells are capable of synthesizing aldosterone to exacerbate damage in muscular dystrophy. | Q45970224 | ||
| Development of a panel of monoclonal antibodies against the mineralocorticoid receptor | Q48692154 | ||
| Human steroid receptors and erb-A gene products form a superfamily of enhancer-binding proteins | Q68180726 | ||
| The molecular basis of muscular dystrophy in the mdx mouse: a point mutation | Q69514522 | ||
| Binding of Steroids to Mineralocorticoid Receptors: Implications for in Vivo Occupancy by Glucocorticoids* | Q72918116 | ||
| Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction | Q83224094 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 277-286 | |
| P577 | publication date | 2017-04-21 | |
| P1433 | published in | Physiological Genomics | Q2506446 |
| P1476 | title | Gene expression effects of glucocorticoid and mineralocorticoid receptor agonists and antagonists on normal human skeletal muscle | |
| P478 | volume | 49 |
Search more.